Wedbush Initiates Coverage On Cartesian Therapeutics with Outperform Rating, Announces Price Target of $38
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Wedbush analyst Martin Fan initiates coverage on Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform rating and announces Price Target of $38.
Wedbush analyst Martin Fan initiates coverage on Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform rating and announces Price Target of $38.